Skin manifestations of COVID-19 in children: Part 3.
Adolescent
Antibodies, Monoclonal, Humanized
/ therapeutic use
COVID-19
/ complications
COVID-19 Testing
Child
Dermatologic Agents
/ therapeutic use
Exanthema
/ drug therapy
Humans
Nicolau Syndrome
/ drug therapy
Pityriasis Rosea
/ pathology
Purpura
/ drug therapy
SARS-CoV-2
Skin Diseases, Viral
/ drug therapy
Urticaria
/ drug therapy
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
12
08
2020
accepted:
13
08
2020
pubmed:
19
11
2020
medline:
7
4
2021
entrez:
18
11
2020
Statut:
ppublish
Résumé
The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In this part of the review, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.
Identifiants
pubmed: 33207021
doi: 10.1111/ced.14483
pmc: PMC7753282
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Dermatologic Agents
0
dupilumab
420K487FSG
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
462-472Informations de copyright
© 2020 British Association of Dermatologists.
Références
Dermatopathology (Basel). 2020 Jun 30;7(1):3-16
pubmed: 32608380
Dermatol Ther. 2020 Jul;33(4):e13495
pubmed: 32458588
Australas J Dermatol. 2020 Aug;61(3):210-216
pubmed: 32255510
Dermatol Ther. 2020 Sep;33(5):e13687
pubmed: 32458536
Med Hypotheses. 2020 Oct;143:109853
pubmed: 32492559
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e293-e294
pubmed: 32330329
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Br J Dermatol. 2020 Oct;183(4):729-737
pubmed: 32562567
Dermatol Ther. 2020 Jul;33(4):e13738
pubmed: 32478949
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e302-e303
pubmed: 32333823
Arch Acad Emerg Med. 2020 Apr 18;8(1):e51
pubmed: 32440662
Pediatr Dermatol. 2020 May;37(3):437-440
pubmed: 32374033
Dermatol Ther. 2020 Jul;33(4):e13469
pubmed: 32347635
Can J Infect Dis Med Microbiol. 2006 Nov;17(6):330-6
pubmed: 18382647
EClinicalMedicine. 2020 Jun 26;24:100433
pubmed: 32766542
Am J Infect Control. 2020 Aug;48(8):933-939
pubmed: 32464297
Clin Exp Dermatol. 2020 Oct;45(7):896-898
pubmed: 32438476
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 33500101
J Dermatolog Treat. 2020 Jun;31(4):325
pubmed: 32238000
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e242-e244
pubmed: 32223004
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Euro Surveill. 2020 May;25(18):
pubmed: 32400364
Infect Dis (Lond). 2020 Jun;52(6):427-429
pubmed: 32233816
Cleve Clin J Med. 2020 May 14;:
pubmed: 32409442
J Am Acad Dermatol. 2020 Apr;82(4):1034
pubmed: 32081700
Br J Dermatol. 2020 Aug;183(2):404-406
pubmed: 32348554
J Dermatolog Treat. 2022 Feb;33(1):569-570
pubmed: 32420788
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e559-e561
pubmed: 32500642
Pediatr Dermatol. 2020 May;37(3):442-446
pubmed: 32445583
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Dermatol Ther. 2020 Jul;33(4):e13666
pubmed: 32447801
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1388-1394
pubmed: 32428303
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e548-e549
pubmed: 32491234
Pediatr Dermatol. 2020 May;37(3):424-434
pubmed: 32320494
JAMA Dermatol. 2020 Jul 1;156(7):819-820
pubmed: 32352486
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e241-e242
pubmed: 32223003
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e295-e297
pubmed: 32302437
Pediatr Infect Dis J. 2020 Aug;39(8):e195-e198
pubmed: 32467457
J Dermatolog Treat. 2022 Mar;33(2):1123-1125
pubmed: 32543328
Dermatol Ther. 2020 Jul;33(4):e13740
pubmed: 32478970
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2620-2629
pubmed: 32474947
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e459-e460
pubmed: 32386447
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
Lancet Respir Med. 2020 Jul;8(7):681-686
pubmed: 32473124
J Am Acad Dermatol. 2020 Aug;83(2):e165-e167
pubmed: 32405123
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
Pediatr Dermatol. 2020 May;37(3):419-423
pubmed: 32396999
Pediatr Dermatol. 2021 Jan;38(1):301-303
pubmed: 33085141
Pediatr Dermatol. 2020 May;37(3):406-411
pubmed: 32386460
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e247-e248
pubmed: 32294265
Dermatol Ther. 2020 Sep;33(5):e13642
pubmed: 32441360